How to Choose a Peptide Clinic: A Due-Diligence Checklist

The peptide therapy landscape has expanded rapidly, and the range of clinic quality spans from excellent physician-supervised practices to operations that amount to little more than a prescription mill with a website. Choosing the wrong clinic does not just waste money — it can mean receiving improperly compounded peptides, missing contraindications, or following protocols without adequate monitoring.

This checklist is designed to help you evaluate peptide clinics before committing to a provider.

Physician credentials: what to verify

Medical license. This is non-negotiable. Every state medical board maintains a public lookup tool where you can verify an active, unrestricted license. Check the specific state where the provider is licensed, as telehealth prescribing across state lines requires licensure in the patient's state.

Board certification. Board certification in a relevant specialty (endocrinology, internal medicine, sports medicine, anti-aging/regenerative medicine) indicates additional training beyond medical school. Certification through the American Board of Medical Specialties (ABMS) or the American Osteopathic Association (AOA) is standard. Some providers hold certification from the American Academy of Anti-Aging Medicine (A4M) — this is a legitimate organization, though its board certification is not ABMS-recognized.

Disciplinary history. State medical board databases also show any disciplinary actions, malpractice settlements, or practice restrictions. A clean record does not guarantee quality, but active disciplinary actions are a clear disqualifier.

What matters less than you think: Impressive-sounding titles ("Director of Peptide Therapy," "Chief Longevity Officer"), social media following, podcast appearances, and testimonials on the clinic website. These are marketing, not credentials.

Compounding pharmacy verification

Since most therapeutic peptides are not commercially manufactured pharmaceuticals, they typically come from compounding pharmacies. The quality of the pharmacy is as important as the prescriber.

503A vs 503B pharmacies:

In the United States, compounding pharmacies operate under two regulatory frameworks. Section 503A pharmacies compound medications based on individual patient prescriptions. They are regulated by state boards of pharmacy and are not required to comply with current Good Manufacturing Practice (cGMP) standards.

Section 503B outsourcing facilities operate under direct FDA oversight, must comply with cGMP standards, and can produce larger batches without patient-specific prescriptions. They undergo FDA inspections and must report adverse events.

What to ask:

Does the clinic source from a 503B outsourcing facility? If 503A, is the pharmacy accredited by PCAB (Pharmacy Compounding Accreditation Board)? Can the pharmacy provide a Certificate of Analysis (CoA) for each peptide batch, including identity testing, purity (HPLC), sterility, endotoxin, and potency? Has the pharmacy received any FDA warning letters? (These are publicly searchable on the FDA website.)

Red flag: A clinic that cannot or will not disclose its compounding pharmacy source. Legitimate clinics are transparent about their supply chain because quality sourcing is a selling point, not a liability.

Bloodwork requirements

Bloodwork is the single best indicator of whether a clinic practices evidence-based peptide therapy or simply sells prescriptions.

Before starting any protocol, a responsible clinic should require:

Baseline bloodwork appropriate to the peptides being prescribed. For GH secretagogues, this means at minimum IGF-1, fasting glucose/insulin or HbA1c, and a comprehensive metabolic panel. For immune-modulating peptides, a CBC with differential. For peptides affecting the thyroid axis, TSH/free T4/free T3. General markers like a lipid panel, CRP, and liver function tests provide baseline health assessment.

During treatment:

Follow-up labs at defined intervals (typically 6-8 weeks into a protocol, then periodically) to assess response and monitor for adverse effects. IGF-1 monitoring for GH secretagogues is essential — without it, dosing is guesswork.

Red flag: Any clinic that prescribes peptides without requiring baseline bloodwork, or that does not schedule follow-up labs, is operating below the standard of care. "We'll order labs if you have symptoms" is not adequate — many peptide effects (e.g., insulin resistance from excessive GH stimulation) can be asymptomatic until significantly advanced.

The consultation: what to look for

The initial consultation reveals how a clinic actually practices. Key indicators:

Medical history review. A thorough intake should cover current medications, supplements, past medical history, family history (cancer history is particularly relevant for GH secretagogues), and current symptoms. This should feel like a medical appointment, not a sales presentation.

Contraindication screening. Responsible providers will screen for contraindications. For GH secretagogues: active malignancy, uncontrolled diabetes, active retinopathy. For immune-modulating peptides: current immunosuppressive therapy, organ transplant history. A provider who does not ask about these conditions is not screening adequately.

Individualized protocol. Cookie-cutter protocols (every patient gets the same peptides at the same doses) are a warning sign. A good provider selects peptides based on your specific complaints, lab results, and health history, then adjusts based on response.

Honest communication about evidence. When discussing specific peptides, listen for how the provider characterizes the evidence. Phrases like "studies show" should be accompanied by context about whether those are animal studies, human case reports, or controlled clinical trials. A provider who presents preclinical animal data as established human evidence is either uninformed or dishonest — neither is acceptable.

Telehealth vs in-person

Both models can deliver quality care, but each has trade-offs:

Telehealth advantages: Broader access to specialized providers (peptide expertise is not evenly distributed geographically), convenience, often lower cost, and adequate for most peptide therapy oversight (which primarily involves history, bloodwork review, and protocol adjustment).

Telehealth limitations: Cannot perform physical examination (relevant for injury assessment before prescribing tissue-repair peptides), injection technique instruction may be less effective via video, and some states have telehealth prescribing restrictions.

In-person advantages: Physical examination, hands-on injection training, direct relationship building, and the ability to perform point-of-care testing.

What matters more than the model: whether the provider practices comprehensive medicine regardless of the delivery format. A thorough telehealth provider who requires labs, conducts detailed intake, and follows up appropriately is preferable to an in-person clinic that rushes through appointments and prescribes without adequate evaluation.

Specific red flags

The following should prompt you to look elsewhere:

• No prescription required. If a clinic sells peptides without a prescriber evaluation, they are not a medical practice. Research peptides sold direct-to-consumer without a prescription exist in a regulatory gray area with significant quality control concerns.
• Guaranteed results. No responsible practitioner guarantees outcomes with peptides, most of which lack robust human clinical trial data.
• Pressure to start immediately. Urgency tactics ("limited supply," "price going up") are sales techniques, not medical practice.
• No follow-up protocol. A single consultation followed by ongoing refills without reassessment is not adequate care.
• Sourcing from overseas or non-compounding suppliers. Peptides should come from licensed US pharmacies (for US patients). International sourcing bypasses regulatory oversight.
• Dismissal of side effects or risks. Every intervention has potential side effects. A provider who presents peptide therapy as risk-free is not providing informed consent.

Cost considerations

Peptide therapy costs vary widely. Expect to pay for the consultation (initial and follow-ups), bloodwork (some clinics include this, others use third-party lab services), the peptides themselves (compounding costs), and supplies (syringes, bacteriostatic water, alcohol swabs).

Total monthly costs typically range from $150-600+ depending on the peptides prescribed, the clinic model, and the compounding pharmacy used. Be wary of both extremes — unusually cheap pricing may reflect inferior compounding, while premium pricing does not automatically indicate superior quality.

The best value comes from a provider who prescribes appropriately (not over-prescribing), monitors response (adjusting or discontinuing based on results), and uses a reputable compounding pharmacy with documented quality control.